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Abstract
Background: Resolvin D1 and D2 are bioactive lipid mediators that are generated from docosahexaenoic acid. Although recent 
preclinical studies suggest that these compounds have antidepressant effects, their mechanisms of action remain unclear.
Methods: We investigated mechanisms underlying the antidepressant effects of resolvin D1 and resolvin D2 in 
lipopolysaccharide (0.8 mg/kg, i.p.)-induced depression model mice using a tail suspension test.
Results: I.c.v. infusion of resolvin D1 (10 ng) and resolvin D2 (10 ng) produced antidepressant effects; these effects were 
significantly blocked by a resolvin D1 receptor antagonist WRW4 (10 µg, i.c.v.) and a resolvin D2 receptor antagonist O-1918 
(10 µg, i.c.v.), respectively. The mammalian target of rapamycin complex 1 inhibitor rapamycin (10 mg/kg, i.p.) and a mitogen-
activated protein kinase kinase inhibitor U0126 (5 µg, i.c.v.) significantly blocked the antidepressant effects of resolvin D1 
and resolvin D2. An AMPA receptor antagonist NBQX (10 mg/kg, i.p.) and a phosphoinositide 3-kinase inhibitor LY294002 (3 
µg, i.c.v.) blocked the antidepressant effects of resolvin D1 significantly, but not of resolvin D2. Bilateral infusions of resolvin 
D1 (0.3 ng/side) or resolvin D2 (0.3 ng/side) into the medial prefrontal cortex or dentate gyrus of the hippocampus produced 
antidepressant effects.
Conclusions: These findings demonstrate that resolvin D1 and resolvin D2 produce antidepressant effects via the mammalian 
target of rapamycin complex 1 signaling pathway, and that the medial prefrontal cortex and dentate gyrus are important brain 
regions for these antidepressant effects. These compounds and their receptors may be promising targets for the development 
of novel rapid-acting antidepressants, like ketamine and scopolamine.
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Introduction
Major depressive disorder is one of the most common psychiat-
ric illnesses, leading to enormous personal and socioeconomic 
burdens (Greenberg et  al., 2015). Because currently available 
monoamine-based antidepressants have significant limita-
tions, including delayed onset of treatment response (weeks to 
months) and low efficacy (approximately one-third of depressed 
patients fail to respond to 2 or more antidepressants and 
are characterized as having treatment-resistant depression) 
(Trivedi et al., 2006), there is a significant unmet medical need 
for more effective and rapid-acting antidepressants. Recent 
clinical studies have shown that ketamine (an NMDA receptor 
antagonist) and scopolamine (a nonselective muscarinic recep-
tor antagonist) produce rapid antidepressant effects (within 
hours) even in treatment-resistant depressed patients (Zarate 
et al., 2006; Ellis et al., 2014). Preclinical studies have revealed 
that the rapid antidepressant effects of these drugs are medi-
ated by activation of mammalian target of rapamycin complex 
1 (mTORC1), a downstream target of phosphoinositide 3-kinase 
(PI3K)/Akt and mitogen-activated protein kinase kinase (MEK)/
extracellular signal-regulated kinase (ERK) signaling, in brain 
regions such as the medial prefrontal cortex (mPFC) and hip-
pocampus (Li et al., 2010; Voleti et al., 2013; Duman et al., 2016). 
These findings suggest that compounds capable of activating 
mTORC1 signaling may have potential to function as rapid-act-
ing antidepressants.
Resolvins are bioactive lipid mediators that are generated 
from the n-3 polyunsaturated fatty acids docosahexaenoic acid 
(DHA) and eicosapentaenoic acid (EPA). Resolvin D1 (RvD1) and 
resolvin D2 (RvD2) are DHA-derived D-series resolvins. RvD1 
activates formyl peptide receptor 2/lipoxin A4 receptor (FPR2/
ALX) and human GPR32 (the murine counterpart of human 
GPR32 remains unknown) (Haitina et al., 2009; Krishnamoorthy 
et al., 2010). Stimulation of FPR2/ALX by RvD1 or lipoxin A4 acti-
vates the PI3K/Akt and MEK/ERK pathways (Odusanwo et al., 
2012; Hodges et al., 2017). Recently, GPR18 has been identi-
fied as a RvD2 receptor (Chiang et al., 2015), and stimulation 
of GPR18 also activates the PI3K/Akt and MEK/ERK signaling 
pathways (Penumarti and Abdel-Rahman, 2014). These findings 
suggest the possibility that RvD1 and RvD2 may produce anti-
depressant effects via activation of PI3K/Akt and/or MEK/ERK 
signaling pathways, and then activation of their downstream 
target, mTORC1, similar to the rapid-acting antidepressants 
ketamine and scopolamine. Thus, the aim of the present study 
was to test this possibility. First, we examined whether i.c.v. 
infusions of RvD1 and RvD2 produced antidepressant effects 
through FPR2/ALX and GPR18, respectively, using lipopolysac-
charide (LPS)-induced depression model mice (O’Connor et al., 
2009; Kang et al., 2011). Second, we examined the involvement 
of mTORC1 and upstream signaling molecules, AMPA receptors, 
PI3K/Akt, and MEK/ERK, in the antidepressant effects of RvD1 
and RvD2. Finally, we examined the roles of the mPFC and the 




Male BALB/c mice (8–12 weeks old, Japan SLC) were group-housed 
(3–5/cage). The mice were maintained at a constant ambient 
temperature (23 ± 1°C) under a 12-h-light/-dark cycle (light on 
7:00 am) with food and water available ad libitum. All experi-
ments were performed with the approval of the Institutional 
Animal Care and Use Committees at Hokkaido University and 
Kanazawa University.
Drugs
RvD1 and RvD2 were obtained as a solution in 100% ethanol from 
Cayman Chemical and stored at -80°C. These solutions were 
diluted with sterile phosphate-buffered saline (PBS) to achieve a 
final ethanol concentration of 2% immediately before use while 
minimizing exposure to light. LPS (serotype 0127:B8; Sigma) 
was dissolved freshly in sterile saline. WRW4 (an FPR2/ALX 
antagonist; Tocris) was dissolved in sterile PBS. O-1918 (a GPR18 
antagonist; Abcam) was dissolved initially in dimethyl sulfoxide 
(DMSO) and then diluted with sterile PBS containing Tween 80 
and ethanol (final concentrations of DMSO, Tween 80, and etha-
nol were 10%, 5%, and 2%, respectively). LY294002 (a PI3K inhibi-
tor; Cayman Chemical) was dissolved initially in DMSO and then 
diluted with sterile PBS containing ethanol (final concentrations 
of DMSO and ethanol were 10% and 2%, respectively). U0126 (a 
MEK inhibitor; LC Laboratories) was dissolved initially in DMSO 
and then diluted with sterile PBS containing Tween 80 and etha-
nol (final concentrations of DMSO, Tween 80, and ethanol were 
5%, 5%, and 2%, respectively). Rapamycin (an mTORC1 inhibi-
tor; LC Laboratories) was dissolved initially in DMSO and then 
diluted with sterile saline containing Tween 80 (final concentra-
tions of DMSO and Tween 80 were both 5%). NBQX disodium salt 
(an AMPA receptor antagonist; Enzo Life Sciences) was dissolved 
in sterile saline.
LPS Challenge
LPS (0.8  mg/kg) or saline was injected i.p. into each mouse at 
a volume of 10 mL/kg. The dose of LPS was selected because it 
could induce depression-like behaviors 24 h after LPS challenge 
without reducing locomotor activity (O’Connor et al., 2009; Kang 
Significance Statement
There is a continuing unmet need for more effective and rapid-acting antidepressants, because currently available 
antidepressants have significant limitations, including delayed onset and low efficacy. Here, we demonstrate that 
docosahexaenoic acid-derived endogenous lipid mediators, resolvin D1 (RvD1) and D2 (RvD2), produce antidepressant 
effects through mechanisms (activation of mTORC1 signaling) similar to those underlying the rapid antidepressant 
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the antidepressant effects of RvD1 and RvD2. Our findings suggest that RvD1 and RvD2 may be promising targets for the 
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et  al., 2011). In the present study, behavioral tests were per-
formed 24 hours after LPS challenge.
Surgery and Drug Treatments
Mice were anesthetized with chloral hydrate (400 mg/kg, i.p.). 
The mice were implanted with a 25-gauge stainless-steel guide 
cannula (o.d., 0.5 mm; i.d., 0.22 mm) above the infusion sites 
in either the lateral ventricle (-0.3 mm rostral, 1.0 mm lateral, 
2.0 mm ventral to bregma; unilateral), mPFC (1.9 mm rostral, 
±0.8  mm lateral, 0.95  mm ventral to bregma, at a 20° angle, 
bilateral), or DG (-1.7 mm rostral, ±1.1 mm lateral, 0.5 mm ven-
tral to bregma, bilateral) (Franklin and Paxinos, 2007). After 
surgery, mice were housed individually and allowed to recover 
for at least 7  days. The i.c.v., intra-mPFC, and intra-DG infu-
sions of drugs were carried out 22 hours after LPS challenge. 
These local infusions of drugs were done in conscious mice 
gently held by the experimenter’s hand. For i.c.v. infusions, a 
33-gauge stainless-steel injection cannula (o.d., 0.2  mm; i.d., 
0.08  mm) was inserted into the guide cannula; the injection 
cannula protruded 0.8 mm from the tip of the guide cannula to 
reach the lateral ventricle. The injection cannula was attached 
to a Hamilton microsyringe mounted on a microinfusion pump 
(Eicom) via PE8 tubing. RvD1 (1 or 10 ng), RvD2 (10 ng), O-1918 
(10 µg), LY294002 (3 µg), U0126 (5 µg), or vehicle was adminis-
tered in a 5-µL volume at a rate of 2.5 µL/min. WRW4 (10 µg, i.c.v.) 
was infused in a 2-µL volume at a rate of 2 µL/min 30 minutes 
prior to i.c.v. infusion of RvD1. After i.c.v. infusions, the injec-
tion cannula was kept in place for another 1 minute to allow 
for diffusion. For intra-mPFC and intra-DG infusions, 33-gauge 
stainless-steel injection cannulae were inserted bilaterally into 
the guide cannulae; the injection cannulae protruded 1.0 and 
Figure 1. Resolvin D1 (RvD1) and resolvin D2 (RvD2) produced antidepressant effects in the lipopolysaccharide (LPS)-induced depression model through formyl peptide 
receptor 2/lipoxin A4 receptor (FPR2/ALX) and GPR18, respectively. (A, D, G) Experimental timeline for LPS challenge (0.8 mg/kg, i.p.), i.c.v. injection, and behavioral test-
ing. (B) Immobility time in the tail suspension test (TST) (interaction: F3,84 = 3.879, P = .0119, n = 9–15). (C) Locomotor activity (LMA) (interaction: F3,48 = 0.3034, P = .8228, 
LPS: F1,48 = 0.001887, P = .9655, treatment: F3,48 = 1.324, P = .2774, n = 6–8). (E) Immobility time in the TST (interaction: F1,34 = 5.203, P = .0289, n = 9–10). (F) LMA (interaction: 
F1,24 = 0.1980, P = .6603, WRW4: F1,24 = 0.2042, P = .6554, treatment: F1,24 = 0.8458, P = .3669, n = 6–8). (H) Immobility time in the TST (interaction: F1,36 = 4.304, P = .0452, n = 
8–11). (I) LMA (interaction: F1,19 = 2.150, P = .1589, O-1918: F1,19 = 1.973, P = .1763, treatment: F1,19 = 1.365, P = .2571, n = 5–6). Data are expressed as means ± SEM. *P < .05, **P 
< .01, ***P < .001 (2-way ANOVA followed by the Newman-Keuls posthoc test).
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Figure 2. Resolvin D1 (RvD1) and resolvin D2 (RvD2) produced antidepressant effects through the mammalian target of rapamycin complex 1 (mTORC1) signaling 
pathway. (A) Experimental timeline for testing the role of mTORC1 in the antidepressant effects of RvD1 and RvD2. Rapamycin (an mTORC1 inhibitor, 10 mg/kg, i.p.) 
was injected 30 minutes prior to i.c.v. infusion of RvD1 or RvD2. (B) Immobility time in the tail suspension test (TST) (interaction: F2,48 = 5.273, P = .0085, n = 5–12). (C) 
Locomotor activity (LMA) (interaction: F2,46 = 0.5457, P = .5831, rapamycin: F1,46 = 1.102, P = .2993, treatment: F2,46 = 0.003064, P = .9969, n = 8–10). Data are expressed as 
means ± SEM. ***P < .001 relative to vehicle; ##P < .01 relative to vehicle + RvD1; ††P < .01 relative to vehicle + RvD2 (2-way ANOVA followed by the Newman-Keuls posthoc 
test).
Figure 3. AMPA receptor-mediated glutamatergic transmission is required for the antidepressant effect of resolvin D1 (RvD1), but not of resolvin D2 (RvD2). (A) 
Experimental timeline for testing the role of glutamatergic transmission in the antidepressant effects of RvD1 and RvD2. NBQX (an AMPA receptor antagonist, 10 mg/
kg, i.p.) was injected 30 minutes prior to i.c.v. infusion of RvD1 or RvD2. (B) Immobility time in the tail suspension test (TST) (interaction: F2,46 = 4.459, P = .0170, n = 6–10). 
(C) Locomotor activity (LMA) (interaction: F2,27 = 0.02636, P = .9740, NBQX: F1,27 = 0.04599, P = .8318, treatment: F2,27 = 0.04579, P = .9553, n = 5 or 6). Data are expressed 
as means ± SEM. *P < .05, **P < .01, ***P < .001 relative to vehicle; ##P < .01 relative to saline + RvD1; $$P < .01 relative to NBQX + vehicle (2-way ANOVA followed by the 
Newman-Keuls posthoc test).
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1.5 mm, respectively, from the tip of guide cannulae to reach 
the mPFC (1.9 mm rostral, ± 0.25 mm lateral, 2.0 mm ventral 
to bregma) and DG (-1.7 mm rostral, ±1.1 mm lateral, 2.0 mm 
ventral to bregma). RvD1 (0.3  ng/side), RvD2 (0.3  ng/side), or 
vehicle was injected bilaterally in a 0.15-µL volume at a rate of 
0.15 µL/min, and the injection cannulae were kept in place for 
another 1 minute. NBQX (10 mg/kg) and rapamycin (10 mg/kg) 
were administered i.p. 30 min prior to i.c.v. infusion. The doses 
of the antagonists and enzyme inhibitors used in the present 
study were determined based on pilot experiments and previ-
ous reports demonstrating significant inhibition of the effect 
of each target molecule (Maeng et al., 2008; Zeni et al., 2012; 
Osborn et al., 2013).
Tail Suspension Test
Each mouse was suspended with its tail fixed to a hook by a 
small piece of adhesive tape. Using an activity measuring and 
recording system equipped with an infrared detector (Supermex, 
CompACT FSS, Muromachi Kikai), the duration of immobility 
was measured automatically for 6 minutes. Mice that climbed 
their tail during the test period were excluded from the analyses.
Locomotor Activity Test
Different cohorts of mice were used for the locomotor activ-
ity test. Each mouse was placed in a gray polyvinyl chloride 
chamber (40 ×  40 ×  35  cm) for 10 minutes. The total distance 
(cm) traveled during this period was automatically measured 
using the EthoVision video tracking system (Noldus Information 
Technology).
Histology
After behavioral tests, histological analyses were performed. 
Mice were euthanized by cervical dislocation, and the brains 
were removed rapidly and frozen on powdered dry ice. Coronal 
sections (50 µm) were prepared on a cryostat, thaw-mounted on 
slides, and stained with thionin to confirm the sites of infusion. 
Mice with incorrect infusion placements were excluded from 
the analyses.
Statistical Analyses
Data are expressed as means ± SEM. Data were analyzed by 
2-way ANOVA followed by the Newman-Keuls posthoc test using 
the GraphPad Prism 6 software (GraphPad Software). Differences 
with P < .05 were considered statistically significant.
Results
Antidepressant Effects of RvD1 and RvD2 via FPR2/
ALX and GPR18, Respectively
To examine the antidepressant effects of RvD1 and RvD2, we used 
the LPS-induced depression model mice. Mice were i.p. injected 
with LPS (0.8 mg/kg) or saline, and then 22 hours later, i.c.v. infu-
sion of RvD1 (1 or 10 ng), RvD2 (10 ng), or vehicle (2% ethanol/PBS) 
was carried out (Figure 1A). The tail suspension test or locomotor 
activity test was conducted 2 hours after i.c.v. infusion. In the tail 
suspension test, LPS challenge significantly increased immobil-
ity in vehicle-infused mice, and this depression-like behavior was 
significantly alleviated by i.c.v. infusion of RvD1 (10 ng) or RvD2 
Figure 4. Phosphoinositide 3-kinase (PI3K)/Akt signaling pathway is required for the antidepressant effect of resolvin D1 (RvD1), but not of resolvin D2 (RvD2). (A) 
Experimental timeline for testing the role of PI3K/Akt signaling pathway in the antidepressant effects of RvD1 and RvD2. LY294002 (a PI3K inhibitor, 3 µg, i.c.v.) was 
infused simultaneously with RvD1 or RvD2. (B) Immobility time in the tail suspension test (TST) (interaction: F2,30 = 5.340, P = .0104, n = 5–8). (C) Locomotor activity (LMA) 
(interaction: F2,27 = 2.161, P = .1347, LY294002: F1,27 = 3.422, P = .0753, treatment: F2,27 = 0.3544, P = .7048, n = 5 or 6). Data are expressed as means ± SEM. **P < .01 relative to 
vehicle; ###P < .001 relative to vehicle + RvD1; $$P < .01 relative to LY294002 + vehicle (2-way ANOVA followed by the Newman-Keuls posthoc test).
580 | International Journal of Neuropsychopharmacology, 2017
(10 ng) (Figure 1B). RvD1 and RvD2 had no effect on immobility in 
saline-injected control mice. There was no effect of LPS challenge 
or i.c.v. infusion of RvD1 or RvD2 on locomotor activity (Figure 1C), 
indicating that the differences observed in the tail suspension 
test were not due to a general change in locomotor activity.
To investigate the role of FPR2/ALX in the antidepressant 
effect of RvD1, WRW4 (10 µg; an FPR2/ALX antagonist) or vehicle 
(PBS) was administered 30 minutes before i.c.v. infusion of RvD1 
(10 ng) (Figure 1D). In the tail suspension test, RvD1 decreased 
immobility significantly in vehicle-pretreated mice, but this 
effect was completely blocked in WRW4-pretreated mice 
(Figure 1E). There was no significant effect of WRW4 and RvD1 
on locomotor activity (Figure  1F). These results indicated that 
RvD1 exerted its antidepressant effects via FPR2/ALX.
Next, we examined the role of GPR18 in the antidepres-
sant effect of RvD2. RvD2 (10  ng) and O-1918 (10  µg; a GPR18 
antagonist) were i.c.v. infused simultaneously (Figure 1G). RvD2 
decreased immobility significantly in vehicle (10% DMSO/5% 
Tween 80/2% ethanol/PBS)-treated mice, but this effect was 
completely blocked by co-infusion with O-1918 (Figure  1H). 
There was no effect of O-1918 and RvD2 on locomotor activity 
(Figure 1I). These results indicated that RvD2 produced its anti-
depressant effects through GPR18.
Involvement of mTORC1 Signaling Pathway in 
Antidepressant Effects of RvD1 and RvD2
Rapamycin (10  mg/kg; an mTORC1 inhibitor) or vehicle (5% 
DMSO/5% Tween 80/saline) was administered i.p.  30 minutes 
before i.c.v. infusion of RvD1 (10  ng), RvD2 (10  ng), or vehicle 
(2% ethanol/PBS) (Figure 2A). RvD1 and RvD2 decreased immo-
bility significantly in vehicle-pretreated mice, but this effect was 
completely blocked by pretreatment with rapamycin (Figure 2B). 
These treatments did not affect locomotor activity (Figure 2C). 
Together, these findings indicate that activation of mTORC1 
signaling mediated the antidepressant effects of RvD1 and RvD2.
Involvement of AMPA Receptors in Antidepressant 
Effect of RvD1, but Not of RvD2
NBQX (10  mg/kg; an AMPA receptor antagonist) or vehicle 
(saline) was administered i.p.  30 minutes before i.c.v. infu-
sion of RvD1 (10 ng), RvD2 (10 ng), or vehicle (2% ethanol/PBS) 
(Figure 3A). RvD1 and RvD2 decreased immobility significantly 
in vehicle-pretreated mice. Pretreatment with NBQX blocked 
the antidepressant effect of RvD1 significantly, but not of RvD2 
(Figure  3B). Locomotor activity was not affected by any of the 
drugs (Figure  3C). These results indicated that activation of 
AMPA receptors was required for the antidepressant effect of 
RvD1, but not of RvD2.
Involvement of PI3K/Akt Signaling Pathway in 
Antidepressant Effect of RvD1, but Not of RvD2
LY294002 (3  µg; a PI3K inhibitor) was i.c.v. coadministered 
with RvD1 (10 ng) or RvD2 (10 ng) (Figure 4A). RvD1 and RvD2 
decreased immobility significantly compared with the vehicle 
(10% DMSO/2% ethanol/PBS)-treated group. Coadministration 
of LY294002 blocked the antidepressant effect of RvD1 signifi-
cantly, but not of RvD2 (Figure 4B). Locomotor activity was not 
Figure 5. Mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway is required for the antidepressant effects of 
resolvin D1 (RvD1) and resolvin D2 (RvD2). (A) Experimental timeline for testing the role of MEK/ERK signaling pathway in the antidepressant effects of RvD1 and RvD2. 
U0126 (a MEK inhibitor, 5 µg, i.c.v.) was infused simultaneously with RvD1 or RvD2. (B) Immobility time in the tail suspension test (TST) (interaction: F2,41 = 4.241, P = 
.0212, n = 6–10). (C) Locomotor activity (LMA) (interaction: F2,36 = 0.01893, P = .9813, U0126: F1,36 = 0.5755, P = .4530, treatment: F2,36 = 0.2122, P = .8098, n = 5–9). Data are 
expressed as means ± SEM. **P < .01 relative to vehicle; ##P < .01 relative to vehicle + RvD1; †††P < .001 relative to vehicle + RvD2 (2-way ANOVA followed by the Newman-
Keuls posthoc test).
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affected by any of the drugs (Figure 4C). These results indicated 
that the antidepressant effects of RvD1, but not of RvD2, were 
mediated by the PI3K/Akt signaling pathway.
Involvement of MEK/ERK Signaling Pathway in 
Antidepressant Effects of RvD1 and RvD2
U0126 (5  µg; a MEK inhibitor) was i.c.v. coadministered with 
RvD1 (10  ng) or RvD2 (10  ng) (Figure  5A). RvD1 and RvD2 
decreased immobility significantly compared with the vehi-
cle (5% DMSO/5% Tween 80/2% ethanol/PBS)-treated group. 
Coadministration of U0126 blocked the antidepressant effects of 
both RvD1 and RvD2 significantly (Figure 5B). Locomotor activity 
was not affected by any of the drugs (Figure 5C). These results 
indicated that the antidepressant effects of both RvD1 and RvD2 
were mediated by the MEK/ERK signaling pathway.
Roles of the mPFC and DG in Antidepressant Effects 
of RvD1 and RvD2
Intra-mPFC infusion of vehicle (2% ethanol/PBS), RvD1 (0.3 ng/
side), or RvD2 (0.3  ng/side) was carried out 2 hours before 
behavioral testing (Figure 6A). Intra-mPFC infusion of RvD1 and 
RvD2 reversed the LPS-induced increase in immobility signifi-
cantly but had no effect on immobility in saline-injected mice 
(Figure 6B). Locomotor activity was not affected by intra-mPFC 
infusion of these compounds (Figure 6C). Intra-DG infusion of 
vehicle (2% ethanol/PBS), RvD1 (0.3 ng/side), or RvD2 (0.3 ng/side) 
was carried out 2 hours before behavioral testing (Figure  7A). 
Intra-DG infusion of RvD1 and RvD2 reversed the LPS-induced 
increase in immobility significantly but had no effect on immo-
bility in saline-injected mice (Figure  7B). Locomotor activity 
was not affected by intra-DG infusion of these compounds 
(Figure  7C). These data demonstrated that the mPFC and the 
DG play an important role in the antidepressant effects of RvD1 
and RvD2.
Discussion
The present study demonstrated that (1) i.c.v. infusions of RvD1 
and RvD2 exerted antidepressant effects in the LPS-induced 
depression model mice, (2) the antidepressant effects of RvD1 
and RvD2 were blocked by pretreatment with rapamycin, and (3) 
local injection of RvD1 and RvD2 into the mPFC or DG exerted 
Figure 6. Intra-medial prefrontal cortex (mPFC) infusion of resolvin D1 (RvD1) and resolvin D2 (RvD2) produced antidepressant effects. (A) Experimental timeline for 
lipopolysaccharide (LPS) challenge (0.8 mg/kg, i.p.), intra-mPFC infusion (RvD1 0.3 ng/side, RvD2 0.3 ng/side or vehicle), and behavioral testing. (B) Immobility time in 
the tail suspension test (TST) (interaction: F2,75 = 5.448, P = .0062, n = 10–16). (C) Locomotor activity (LMA) (interaction: F2,32 = 0.1079, P = .8981, LPS: F1,32 = 3.629, P = .0658, 
treatment: F2,32 = 0.07019, P = .9324, n = 6 or 7). (D) Schematic representation of mPFC infusion sites (plates are from Franklin and Paxinos, 2007). Data are expressed as 
means ± SEM. **P < .01, ***P < .001 (2-way ANOVA followed by the Newman-Keuls posthoc test).
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antidepressant effects. Although previous studies reported the 
antidepressant effects of peripherally administered RvD1 and 
RvD2 in rodent models of myocardial infarct- (Gilbert et  al., 
2014) and fibromyalgia- (Klein et  al., 2014) associated depres-
sion, to our knowledge, these are the first reported results to 
suggest that RvD1 and RvD2 act on brain regions, such as the 
mPFC and DG, to exert antidepressant effects via activation of 
mTORC1 signaling, similar to rapid-acting antidepressants, such 
as ketamine and scopolamine (Li et al., 2010; Voleti et al., 2013; 
Duman et al., 2016).
Low-dose ketamine and scopolamine preferentially block 
NMDA and M1 acetylcholine receptors on GABAergic interneu-
rons, respectively, leading to increased glutamate release in 
the mPFC via presynaptic disinhibition and activation of AMPA 
receptors (Moghaddam et  al., 1997; Voleti et  al., 2013; Duman 
et al., 2016; Wohleb et al., 2016b). AMPA receptor activation results 
in elevation of the number and function of spine synapses in 
the mPFC through activity-dependent BDNF release and subse-
quent activation of TrkB and the downstream mTORC1 pathway 
to exert their antidepressant effects (Duman et  al., 2016). The 
present study demonstrates the involvement of mTORC1, AMPA 
receptors, PI3K/Akt, and MEK/ERK signaling pathways in the 
antidepressant effects of RvD1, suggesting that the underlying 
mechanism of the antidepressant effect of RvD1 may be similar 
to those of ketamine and scopolamine. In contrast, the antide-
pressant effect of RvD2 was not blocked by NBQX or LY294002, 
whereas the effect was fully blocked by U0126 and rapamycin. 
These results suggest that RvD2 and its receptor, GPR18, require 
activation of the MEK/ERK pathway and downstream mTORC1 
signaling, but not AMPA receptor-mediated glutamatergic trans-
mission or PI3K/Akt signaling, to exert an antidepressant effect. 
Further studies are needed to fully determine the signaling 
pathway(s) for the antidepressant effects of RvD1 and RvD2.
Although the mechanisms underlying the pathophysiology 
and treatments of depression remain unclear, there is grow-
ing evidence that inflammatory responses, including neu-
trophil infiltration into the brain and increased expression of 
proinflammatory mediators, are involved in the neurobiology 
of depression, and that antiinflammatory agents produce anti-
depressant effects (Aguilar-Valles et  al., 2014; He et  al., 2016; 
Wohleb et  al., 2016a). RvD1 and RvD2 exert antiinflammatory 
and pro-resolving actions in various animal models of periph-
eral inflammation (Ji et al., 2011; Serhan, 2014). Because the LPS-
induced depression model is an inflammation-based model 
Figure 7. Intra-dentate gyrus (DG) infusion of resolvin D1 (RvD1) and resolvin D2 (RvD2) produced antidepressant effects. (A) Experimental timeline for lipopolysaccha-
ride (LPS) challenge (0.8 mg/kg, i.p.), intra-mDG infusion (RvD1 0.3 ng/side, RvD2 0.3 ng/side or vehicle), and behavioral testing. (B) Immobility time in the tail suspension 
test (TST) (interaction: F2,45 = 4.432, P = .0175, n = 7–11). (C) Locomotor activity (LMA) (interaction: F2,29 = 0.1067, P = .8992, LPS: F1,29 = 1.957, P = .1725, treatment: F2,29 = 0.1267, 
P = .8814, n = 5–7). (D) Schematic representation of DG infusion sites (plates are from Franklin and Paxinos, 2007). Data are expressed as means ± SEM. *P < .05, **P < .01 
(2-way ANOVA followed by the Newman-Keuls posthoc test).
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(O’Connor et al., 2009; Kang et al., 2011), RvD1 and RvD2 may 
alleviate the LPS-induced depression-like behaviors via antiin-
flammatory actions, such as the inhibition of neutrophil chem-
otaxis and reduced expression of proinflammatory mediators. 
However, a recent study showed that repeated i.c.v. infusion of 
RvD2 increased not only an antiinflammatory cytokine, IL-10, 
but also a proinflammatory cytokine, IL-6, in the hypothalamus 
of high-fat diet-fed mice (Pascoal et al., 2017). They also dem-
onstrated that repeated i.c.v. infusion of RvD2 did not reduce 
high-fat diet-induced elevation of IL-1β or TNF-α mRNA levels 
in the hypothalamus. These findings suggest that the antiin-
flammatory effects of RvD1 or RvD2 in the brain may be limited. 
Further studies are needed to determine whether antiinflam-
matory and/or pro-resolving properties of RvD1 and RvD2 con-
tribute to their antidepressant effects.
The mPFC and DG are the brain regions implicated in the 
pathophysiology of depression and the actions of antidepres-
sants (Warner-Schmidt and Duman, 2006; Duman et al., 2016). 
In this study, we demonstrated that intra-mPFC and intra-DG 
injections of RvD1 and RvD2 exerted antidepressant effects, 
suggesting that these brain regions are sites of action of these 
compounds. A  recent study showed that Alox15, the enzyme 
that metabolizes DHA to 17S-hydroxy-DHA, a precursor mol-
ecule of RvD1 and RvD2, is expressed highly in the PFC and hip-
pocampus, and localized at neuronal dendrites (Shalini et  al., 
2017). Inhibition or knockdown of Alox15 in the PFC signifi-
cantly decreased RvD1 levels, blocked long-term potentiation 
in the hippocampo-PFC pathway, and impaired spatial working 
memory. These findings indicate that endogenous 17S-hydroxy-
DHA and its metabolites, RvD1 and RvD2, play an important role 
in neuronal functions in the PFC and hippocampus. To deter-
mine the precise cellular mechanisms underlying the effects of 
RvD1 and RvD2 in these brain regions, further studies, including 
histological analyses for expression patterns of FPR2/ALX and 
GPR18 and electrophysiological analyses of the effects of RvD1 
and RvD2 on synaptic transmission, are needed. Nevertheless, 
the current study provides evidence that RvD1 and RvD2 ame-
liorate depression-like behaviors through the mTORC1 signaling 
pathway, suggesting that these compounds and their receptors 
may be promising targets for the development of novel, rapid-
acting antidepressants.
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